Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 2Lung Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1

Interventions

pembrolizumab 19Docetaxel 9atezolizumab 8Cetuximab 8Nivolumab 7cemiplimab 6Ipilimumab 4Immune Checkpoint Inhibitors 4Gemcitabine 4Drug Therapy 4spartalizumab 3palbociclib 3fludarabine 3durvalumab 3avelumab 3Trastuzumab 3Radiotherapy 3Paclitaxel 3Oncolytic Virotherapy 3Irinotecan 3Fulvestrant 3Fluorouracil 3Cyclophosphamide 3Carboplatin 3Bortezomib 3Blood Specimen Collection 3seribantumab 2selpercatinib 2pazopanib 2motexafin gadolinium 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Canagliflozin × Breast × Clear all
NCT04073680 2020-05-21

A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors

Petra Pharma

Phase 1/2 Unknown
60 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡